2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 265

Prevalence of Medicinal Marijuana Use Among 1000 Rheumatology Patients Attending a Community-Based Rheumatology Clinic: A Prospective Cross-Sectional Study
Abstract Number: 418

Prevalence of Morning Stiffness in a US Registry Population of Rheumatoid Arthritis Patients
Abstract Number: 1186

Prevalence of MRI Spinal Lesions Typical for Axial Spondyloarthritis in Patients with Inflammatory Back Pain
Abstract Number: 71

Prevalence of Pain Reporting in Different Ethnic Groups in the UK: Results from a Large Biobank
Abstract Number: 2193

Prevalence of Raynaud’s Phenomenon and Nailfold Capillaroscopic Abnormalities in Fabry’s Disease: A Cross-Sectional Study
Abstract Number: 2024

Prevalence of Rheumatoid Arthritis in French West Indies, an African Ancestry Population. the Eppra Study
Abstract Number: 1285

Prevalence of Risk Factors for Gastrointestinal Side Effects of Drugs for the Treatment of Pain in Rheumatic Diseases and the Provision of Gastroprotective Treatment – Results of a Large Non-Intervention Study
Abstract Number: 40

Prevalence of Spondyloarthritis (ASAS Criteria) in First-Degree Relatives of Patients with Ankylosing Spondylitis
Abstract Number: 2602

Prevalence of Subclinical Atherosclerosis in Patients with Spondyloarthritis without Clinically Evident Cardiovascular Disease Using Carotid Intima-Media Thickness
Abstract Number: 691

Prevalence of Subclinical Echocardiographic Abnormalities in Patients with Systemic Lupus Erythematosus (SLE)
Abstract Number: 142

Prevalence of Subclinical Entheseal Involvement in Patients with Paediatric Inflammatory Bowel Disease: An Ultrasonographic Study
Abstract Number: 141

Prevalence of Subclinical Enthesopathy in Asymptomatic First Degree Relatives of Patients with Spondyloarthritis
Abstract Number: 2423

Prevalence of Subclinical Synovitis Detected By Ultrasound in Rheumatoid Arthritis and Psoriatic Arthritis Patients Receiving Anti-TNF-α Therapy with Extended Interval of Administration
Abstract Number: 1418

Prevalence of Vitamin D Deficiency in Rheumatoid Arthritis
Abstract Number: 1706

Prevention of SU5416-Induced Pulmonary Hypertension in a TGFβ Dependent Genetic Mouse Model of Scleroderma Using the Endothelin Receptor Antagonist Macitentan

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].